Format

Send to

Choose Destination
See comment in PubMed Commons below
Hematology Am Soc Hematol Educ Program. 2011;2011:30-5. doi: 10.1182/asheducation-2011.1.30.

Genomics of AML: clinical applications of next-generation sequencing.

Author information

1
Division of Oncology, Department of Medicine, Washington University School of Medicine, St Louis, MO, USA.

Abstract

In the past decade, a series of technological advances have revolutionized our ability to interrogate cancer genomes, culminating in whole-genome sequencing, which provides genome-wide coverage at a single base-pair resolution. As sequencing technologies improve and costs decrease, it is likely that whole-genome sequencing of cancer cells will become commonplace in the diagnostic workup of patients with acute myelogenous leukemia (AML) and other cancers. The unprecedented molecular characterization provided by whole-genome sequencing offers the potential for an individualized approach to treatment in AML, bringing us one step closer to personalized medicine. In this chapter, we discuss how next-generation sequencing is being used to study cancer genomes. Recent publications of whole-genome sequencing in AML are reviewed and current limitations of whole-genome sequencing are examined, as well as current and potential future clinical applications of whole-genome sequencing.

PMID:
22160009
DOI:
10.1182/asheducation-2011.1.30
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for HighWire
    Loading ...
    Support Center